Engineered immune cells take on lymphoma and leukemia in early trial
NCT ID NCT05878184
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 37 times
Summary
This early-phase study tests SC291, a type of immunotherapy made from donor cells, in people with certain blood cancers (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or not responded to other treatments. The goal is to check if it is safe and to get an early look at whether it can shrink tumors. Only 16 participants are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Linear Clinical Research Ltd
Nedlands, Western Australia, 6009, Australia
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Northside Hospital
Atlanta, Georgia, 30342, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Stanford Cancer Institute
Palo Alto, California, 94304, United States
-
University of Kansas Medical Center
Fairway, Kansas, 66205, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SC291 (an allogeneic CAR T cell therapy)
What this could lead to
If it works, this could point toward a more accessible, off-the-shelf CAR T treatment for certain blood cancers.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, so it may not show strong anti-tumor effects. There are also risks of serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.